Developing a deep, sustainable pipeline of novel neurobehavioral therapeutics
We have built a growing pipeline of investigational therapeutics. We have internal discovery capabilities and expect to grow our pipeline both organically and through partnerships.
BTRX-335140 (a selective antagonist for kappa opioid receptor): We are conducting a Phase 2 proof-of-concept study of BTRX-335140 in a subpopulation of patients with major depressive disorder. Phase 1 studies in healthy volunteers showed that BTRX-335140 was well tolerated, exhibited favorable pharmacokinetics and engaged the target receptor in the brain at levels projected to be effective in treating symptoms relevant to depression and other CNS disorders.
BTRX-323511 (a selective antagonist for the vasopressin 1a receptor): We expect to start Phase 1 development in early 2020.
- Phase 1
- Phase 2
- Phase 3